Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Signed, written IRB-approved Informed Consent
Histologically or cytologically confirmed relapsed or refractory solid tumors for which no standard therapy exists
ECOG (WHO) performance status 0-1
Life expectancy of at least 3 months
Age >=18 years
A negative pregnancy test (if female in reproductive years)
Acceptable liver and renal function
Acceptable hematologic status
10. Previous cancer therapy is allowed with the exclusion of experimental CDK2 inhibitors. Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy must be completed within one month prior to study entry
Use of effective contraceptive methods if men and women of child producing potential
Capability to swallow capsules intact
Grade <=1 retinopathy

Exclusion Criteria:

In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
Known brain metastases
Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Pregnant or breast feeding women
Unwillingness or inability to comply with procedures required in this protocol
Known infection with HIV, active hepatitis B or hepatitis C
Diabetes mellitus uncontrolled, or with clinical evidence of diabetic retinopathy, severe peripheral vascular disease or diabetic ulcers
Current enrollment in another clinical trial
Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation (lactose intolerance)
Previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease, multiple sclerosis, stroke and cerebellar injury
Gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis, or short gut syndrome) that would impact on drug absorption
Chronic/intensive use of antacid or H2 receptor antagonists
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the investigator and/or the sponsor.